Ben Fidler
Lead Editor | @BentheFidlerBen is a lead editor for BioPharma Dive. He is a veteran business journalist with more than 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
893 articles by Ben Fidler
-
Allogene CEO to step down; Agios drug fails key test
May 29, 2026 -
Pfizer, Innovent strike $10B cancer drug deal
May 29, 2026 -
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
May 26, 2026 -
Relay drug shows early promise against rare blood vessel diseases
May 19, 2026 -
Regeneron immunotherapy combo comes up short in melanoma trial
May 18, 2026 -
With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
May 14, 2026 -
FDA chief Marty Makary resigns from agency, ending tumultuous tenure
May 12, 2026 -
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
May 12, 2026 -
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
May 11, 2026 -
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
May 8, 2026 -
Avalo shares spike on skin drug data; BioNTech to cut staff
May 6, 2026 -
Cytokinetics heart drug scores in closely watched trial
May 5, 2026 -
With $97M, Latus pursues a different kind of Huntington’s gene therapy
May 4, 2026 -
UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
May 4, 2026 -
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
May 1, 2026 -
Pfizer deals extend patent life for a top-selling rare disease drug
April 28, 2026 -
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
April 28, 2026 -
Lilly to buy startup Ajax in bid for a better JAK drug
April 27, 2026 -
Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder
April 27, 2026 -
Merck’s fast-ascending kidney cancer drug hits a setback
April 21, 2026 -
Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout
April 20, 2026 -
AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
April 20, 2026 -
Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool
April 17, 2026 -
Roche to start new Elevidys study following setback in Europe
April 16, 2026 -
Lilly boosts ADC portfolio with CrossBridge Bio deal
April 14, 2026
